Thrombin is defined as a naturally occurring enzyme which converts fibrinogen into fibrin and results into clot formation. Thrombin has been invented from different sources and called as a hemostatic aid. Thrombin was found from bovine plasma and now thrombin is derived from the recombinant sources and human plasma. Thrombin is used at the end of the coagulation cascade and it is used as clotting factor. Thrombin is also used in the prothrombin, formation of antibodies against thrombin, cardiolipin and factor V. Thrombin is also used during operation near larger vessels is conducted to prevent disseminated intravascular coagulation (DIC) and death.

In adults, the ordinary blood level of anti-thrombin movement has been estimated to be around 1.1 units/mL. Infant levels of thrombin consistently increment after birth to arrive at typical grown-up levels from a degree of around 0.5 units/mL 1 day after birth to a degree of around 0.9 units/mL following a half year of life. Thrombin collaborates with thrombomodulin to increase the strength of the fibrin.

COVID-19 Scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

Increase in number of cases for acquired blood coagulating diseases such as hemophilia, Von Willebrand disease are the factors contributing to the market growth. Also, increasing use of thrombin by the patients will drive the market growth. Increase in the number of accidents and injuries are the factors influencing the market growth. According to WHO report, it is found that 1.35 million individuals die every year, because of street car accidents and 20-50 million additional individuals endure non-lethal wounds, with many acquiring a handicap because of their physical issue this would further contribute to the thrombin market growth.

Thrombin is used in safer hemostatic condition and post-operative complications which would drive market growth. The only source of thrombin is human plasma and due to its risk of transmitting infectious agents which is restraining market growth. Thrombin plays a significant role in the surgeries around the world and is used in the careful hemostasis, which is driving the thrombin market growth. Human thrombin was replaced with bovine thrombin because of its expanded productivity in surgeries.

Key benefits of the report:

• This study presents the analytical depiction of the global thrombin market along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints and opportunities along with detailed analysis of the global thrombin market share.
• The current market is quantitatively analyzed from 2020 to 2027 to highlight the growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the thrombin market.
• The report provides a detailed global thrombin market analysis based on competitive intensity and how the competition will take shape in coming years. 

Questions answered in the thrombin market research report:

• Who are the leading market players active in the thrombin market?
• What are the current trends that will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities in the market?
• What can be the challenges for the thrombin market in future?
• What are the projections for the future that will help in taking further strategic steps?

 Key Market Segments

 
Key Market Players

• Baxter
• Shanghai RAAS
• Bayer
• Omrix Biopharmaceuticals Ltd.
• CSL
• Octapharma
• Grifols
• Pfizer
• Haematologic Technologies Inc.
• GE Healthcare
• Hualan Biological